Clinical trials: Anti-PD-1
Solid Tumor, Lymphoma
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
This is a Phase I study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, LB1410, is safe, tolerable and efficacious in participants with advanced solid tumors or lymphoma.
- Trial name
- NCT05357651
- Testing
- LB1410
- Where
- China
- Volunteers
- 100 people
- Sponsor
- L & L Bio Co., Ltd., Ningbo, China
Melanoma, Melanoma (Skin)
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with…
- Conditions
- Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
- Trial name
- OCTAVA (NCT05732805)
- Testing
- BCD-217, BCD-100
- Where
- 63 sites in Belarus, India and 1 more
- Volunteers
- 270 people
- Sponsor
- Biocad
Solid Tumor
A Study of AK131 in Patients With Advanced Solid Tumors
This is a phase Ia/Ib study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK131 in advanced solid tumor patients
- Trial name
- NCT06166888
- Testing
- AK131
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Akeso
Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer
The intratumoral microbiota is a key modulator of the tumor immune microenvironment. This study aims to clinically validate a novel, AI-driven digital pathology biomarker-the Microbial-Sensory Coupling (MSC) index-which measures…
- Trial name
- NCT07745322
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cervical Cancer, Cervix Cancer
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Cervical cancer is the second-most common cancer in the world and is a leading cause of cancer death among women in developing countries.
- Conditions
- Cervical Cancer, Cervix Cancer, Cervix Neoplasm
- Trial name
- NCT04651127
- Testing
- Toripalimab + Chidamide
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Sun Yat-sen University
Cancer, Immune Defect
Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors
Our knowledge on cardiovascular side effects of immune checkpoint inhibitors (ICIs) is restricted to this date to observational retrospective data (mainly case series and pharamcovigilance analysis).
- Conditions
- Cancer, Immune Defect, Cardiovascular Abnormalities
- Trial name
- AMICI (NCT04586894)
- Testing
- Cardiac MRI, Smart cloth, Biobanking
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ovarian Cancer Stage IV, Ovarian Cancer Stage III
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
This is an open label, non-randomized, 2-stage phase II, single arm study to determine the efficacy of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide vaccine as a priming mechanism to prevent anti-PD1 resistance…
- Conditions
- Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3
- Trial name
- NCT05479045
- Testing
- NY-ESO-1 Peptide vaccine, Toripalimab-tpzi
- Sponsor
- Georgetown University
Recurrent Glioblastoma
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
The purpose of this study is to evaluate the clinical efficacy and safety of Tislelizumab (one anti-PD-1 antibody same as nivolumab approved in China) in combination with bevacizumab in patients with recurrent or progressive…
- Trial name
- NCT05540275
- Testing
- Tislelizumab plus Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Provincial People's Hospital
Colorectal Cancer Metastatic, Colon Cancer
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
This clinical trial will be conducted as a single-center, open-label, Phase I/2 trial to evaluate the feasibility and safety of Yttrium-90 radioembolization (Y90-RE) in combination with a fixed dose of of immunotherapy…
- Conditions
- Colorectal Cancer Metastatic, Colon Cancer, Metastatic Colorectal Cancer, Rectal Cancer
- Trial name
- iRE-C (NCT04108481)
- Testing
- Durvalumab, Yttrium-90 RadioEmbolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Iowa
Advanced Melanoma, Non-small Cell Lung Cancer
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
This trial is a phase 1/1b study to evaluate the safety, efficacy, and tolerability of APX005M in combination with nivolumab and cabiralizumab.
- Conditions
- Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03502330
- Testing
- APX005M, Cabiralizumab, Nivolumab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Yale University
Hepatocellular Carcinoma, Hepatocellular Cancer
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with/without local ablation).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer, Colorectal Carcinoma
- Trial name
- NCT04912765
- Testing
- Neoantigen Dendritic Cell Vaccine, Nivolumab
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- National Cancer Centre, Singapore
Gastric Cancer, Randomized Controlled Study
Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
The study is a multicenter, open-label, randomized controlled clinical study. The purpose of the study is to evaluate the efficacy and safety of apatinib combined with chemotherapy versus chemotherapy in second-line gastric…
- Trial name
- NCT05029453
- Testing
- Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
This is a single-arm, multicenter phase II clinical study. The aim is to evaluate the safety, tolerability, and anti-tumor activities of AK104(a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced gastric…
- Trial name
- NCT04556253
- Testing
- AK104
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Peking University
Healthy Male Adults Participants
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations
This study is to evaluate the pharmacokinetic (PK) similarity of AK104 (an anti-PD-1/CTLA-4 bispecific antibody) from the proposed new manufacturing site and the approved original site in healthy male participants.
- Trial name
- NCT07619001
- Testing
- AK104 (New Site), AK104 (Original Site)
- Where
- China
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Akeso
Neoplasms, Carcinoma, Squamous
Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Nivolumab + carboplatin + paclitaxel in 25 newly diagnosed patients with primary tracheal squamous cell carcinoma.
- Conditions
- Neoplasms, Carcinoma, Squamous, Antineoplastic Agents
- Trial name
- GALAXY-1 (NCT05964101)
- Testing
- Nivolumab Injection [Opdivo]
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Advanced Solid Tumors
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors
To investigate the safety and tolerability of GLS-010 in subjects with advanced solid tumors (mainly gastric cancer, esophageal cancer).
- Trial name
- NCT03713905
- Testing
- GLS-010
- Where
- China
- Volunteers
- 293 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
HIV Infections
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
The purpose of this study was to evaluate the safety and immunotherapeutic activity of an anti-PD-1 antibody (cemiplimab) in participants with HIV-1 on suppressive combination antiretroviral therapy (cART).
- Trial name
- NCT03787095
- Testing
- Cemiplimab
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Background: Squamous cell carcinoma is a type of cancer that can cause tumors on the head and neck (HNSCC). Even with treatment, less than 50% of people with certain types of HNSCC survive for 5 years.
- Conditions
- Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck, Stage IV Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT06161545
- Testing
- PD-L1 t-haNK cells, pembrolizumab, N-803
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
This study is open to Japanese adults with different types of advanced cancer (solid tumors). People can join the study if their cancer has spread, and previous treatments were not successful or no treatments exist.
- Trial name
- NCT07176975
- Testing
- BI 1831169, nivolumab
- Where
- Japan
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Melanoma, Cancer
BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs
BLOOD is an investigator-initiated, multicenter, prospective biomarker study in patients with advanced melanoma treated with anti-PD-1 monotherapy in the first-line setting.
- Trial name
- BLOOD (NCT04473027)
- Testing
- Blood sample collection
- Where
- Belgium
- Volunteers
- 3 people
- Sponsor
- University Hospital, Ghent
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.